This company seems to have been delisted
Reason: Acquired by Amgen
Last recorded trade on: November 25, 2022
Source: https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash
Reason: Acquired by Amgen
Last recorded trade on: November 25, 2022
Source: https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash
ChemoCentryx
CCXI
$51.99
Share price
0.00%
Change (1 day)
33.72%
Change (1 year)
Categories
Revenue for ChemoCentryx (CCXI)
Revenue in 2022 (TTM): $37.2 Million USD
According to ChemoCentryx's latest financial reports the company's current revenue (TTM 
) is $37.2 Million USD. In 2021 the company made a revenue of $31.9 Million USD a decrease over the revenue in the year 2020 that were of $64.39 Million USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for ChemoCentryx from 2011 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | $37.2 M | 16.61% |
| 2021 | $31.9 M | -50.46% |
| 2020 | $64.39 M | 79.11% |
| 2019 | $35.95 M | -16.15% |
| 2018 | $42.87 M | -48.03% |
| 2017 | $82.49 M | 621.44% |
| 2016 | $11.43 M | |
| 2015 | N/A | |
| 2014 | N/A | -100% |
| 2013 | $6.06 M | 11.83% |
| 2012 | $5.41 M | -82.89% |
| 2011 | $31.67 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 | $9.67 B | 25,910.48% | 🇺🇸 USA |
 | $56.33 B | 151,335.48% | 🇺🇸 USA |
 | $40.18 B | 107,912.25% | 🇬🇧 UK |
 | $48.30 B | 129,738.71% | 🇺🇸 USA |
 | $88.82 B | 238,666.13% | 🇺🇸 USA |
 | $33.42 B | 89,749.46% | 🇺🇸 USA |
 | $63.62 B | 170,937.63% | 🇺🇸 USA |
 | $16.54 B | 44,370.43% | 🇮🇱 Israel |
 | $64.16 B | 172,394.62% | 🇺🇸 USA |